URGN UroGen Pharma Ltd
Price (delayed)
$11.2
Market cap
$516.26M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.96
Enterprise value
$466.58M
Urogen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel,
Highlights
The company's EPS rose by 17% YoY and by 4.2% QoQ
The gross profit rose by 11% year-on-year
UroGen Pharma's equity has plunged by 135% from the previous quarter but it has soared by 87% YoY
The quick ratio has contracted by 33% from the previous quarter but it has grown by 14% YoY
The net income is down by 24% YoY and by 10% QoQ
URGN's debt is up by 24% year-on-year
Key stats
What are the main financial stats of URGN
Market
Valuations
Earnings
Shares outstanding
46.09M
Market cap
$516.26M
Enterprise value
$466.58M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
5.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.16
Revenue
$90.4M
Gross profit
$81.52M
Operating income
-$96.78M
Net income
-$126.87M
EBIT
-$111.52M
EBITDA
-$110.34M
Free cash flow
-$97.06M
Per share
Balance sheet
Liquidity
EPS
-$2.96
EPS diluted
-$2.96
Free cash flow per share
-$2.26
Book value per share
-$0.21
Revenue per share
$2.11
TBVPS
$6.66
Total assets
$285.71M
Total liabilities
$294.51M
Debt
$123.39M
Equity
-$8.8M
Working capital
$230.19M
Debt to equity
-14.02
Current ratio
6.01
Quick ratio
5.62
Net debt/EBITDA
0.45
Margins
Efficiency
Dividend
EBITDA margin
-122.1%
Gross margin
90.2%
Net margin
-140.4%
Operating margin
-107.1%
Return on assets
-47.4%
Return on equity
-7,363.6%
Return on invested capital
-61.9%
Return on capital employed
-46.5%
Return on sales
-123.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
URGN stock price
How has the UroGen Pharma stock price performed over time
Intraday
5.36%
1 week
-2.78%
1 month
18.39%
1 year
-20.51%
YTD
5.16%
QTD
1.27%
Financial performance
How have UroGen Pharma's revenue and profit performed over time
Revenue
$90.4M
Gross profit
$81.52M
Operating income
-$96.78M
Net income
-$126.87M
Gross margin
90.2%
Net margin
-140.4%
The company's operating income fell by 48% YoY and by 16% QoQ
The operating margin is down by 35% year-on-year and by 14% since the previous quarter
The net income is down by 24% YoY and by 10% QoQ
URGN's net margin is down by 14% year-on-year and by 9% since the previous quarter
Growth
What is UroGen Pharma's growth rate over time
Valuation
What is UroGen Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
5.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.16
The company's EPS rose by 17% YoY and by 4.2% QoQ
UroGen Pharma's equity has plunged by 135% from the previous quarter but it has soared by 87% YoY
The price to sales (P/S) is 95% lower than the 5-year quarterly average of 93.4 and 17% lower than the last 4 quarters average of 6.1
The revenue has grown by 9% YoY
Efficiency
How efficient is UroGen Pharma business performance
The ROA has increased by 33% YoY
The company's return on sales fell by 22% YoY and by 11% QoQ
URGN's return on invested capital is down by 10% year-on-year and by 6% since the previous quarter
Dividends
What is URGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for URGN.
Financial health
How did UroGen Pharma financials performed over time
UroGen Pharma's total assets is 3% lower than its total liabilities
UroGen Pharma's total assets has surged by 60% YoY but it has decreased by 5% QoQ
The current ratio is down by 33% since the previous quarter but it is up by 11% year-on-year
UroGen Pharma's equity has plunged by 135% from the previous quarter but it has soared by 87% YoY
URGN's debt is up by 24% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.